Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4901MR)

This product GTTS-WQ4901MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4901MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2693MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ8969MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ10718MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ9794MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ8130MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ14415MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ1515MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ13538MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW